Continuous cardiac output and hemodynamic monitoring: high temporal correlation between plasma TNF-α and hemodynamic changes during a sepsis-like state in cancer immunotherapy
暂无分享,去创建一个
[1] F. Ognibene,et al. Validation of continuous thermodilution cardiac output in critically ill patients with analysis of systematic errors. , 1998, Journal of critical care.
[2] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[3] R. Ohta,et al. Evaluation of a continuous cardiac output and mixed venous oxygen saturation catheter in critically ill surgical patients. , 1997, Critical care medicine.
[4] J. Cavaillon,et al. Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome , 1997, Infection and immunity.
[5] L. Brandt,et al. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?]. , 1996, Der Anaesthesist.
[6] A. Girbes,et al. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. , 1996, Critical care medicine.
[7] C. Sprung,et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.
[8] R. Motzer,et al. Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma , 1995, Cancer.
[9] M. Haller,et al. Evaluation of a new continuous thermodilution cardiac output monitor in cardiac surgical patients: a prospective criterion standard study. , 1995, Critical care medicine.
[10] G. Hempelmann,et al. Is continuous cardiac output measurement using thermodilution reliable in the critically ill patient? , 1994, Critical care medicine.
[11] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[12] F. Cerra,et al. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. , 1994, JAMA.
[13] E. Moore,et al. Effects of accidental trauma on cytokine and endotoxin production. , 1993, Critical care medicine.
[14] W. Shoemaker,et al. Effects of accidental trauma on cytokine and endotoxin production , 1993, Critical care medicine.
[15] R. Bone. Guidelines for the Use of Innovative Therapies in Sepsis , 1993 .
[16] J. Cavaillon,et al. Circulating cytokines: the tip of the iceberg? , 1992, Circulatory shock.
[17] J. Cavaillon,et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.
[18] J. Cavaillon,et al. Dissociation between plasma and monocyte‐associated cytokines during sepsis , 1991, European journal of immunology.
[19] J. Schellekens,et al. Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock , 1990 .
[20] L. G. Thijs,et al. Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .
[21] P. Brandtzaeg,et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome , 1989, The Journal of experimental medicine.
[22] E. Girardin,et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.
[23] J. Sculier,et al. Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer , 2005, Intensive Care Medicine.
[24] R. Bone,et al. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. , 1996, Critical care medicine.
[25] M. Haller,et al. Evaluation of a new continuous thermodilution cardiac output monitor in critically ill patients: a prospective criterion standard study. , 1995, Critical care medicine.
[26] R. Tompkins,et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.
[27] J. Schellekens,et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. , 1990, The Journal of infectious diseases.
[28] L A Aarden,et al. Increased plasma levels of interleukin-6 in sepsis. , 1989, Blood.
[29] F. Ognibene,et al. Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Dinarello. Interleukin-1 and its biologically related cytokines. , 1989, Advances in immunology.
[31] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.